These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 29579856)

  • 41. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir.
    Mattes FM; Hainsworth EG; Hassan-Walker AF; Burroughs AK; Sweny P; Griffiths PD; Emery VC
    J Infect Dis; 2005 Jan; 191(1):89-92. PubMed ID: 15593008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preemptive therapy for the prevention of cytomegalovirus disease in renal transplant recipients: our preliminary experience.
    Paudice N; Mehmetaj A; Zanazzi M; Moscarelli L; Piperno R; Di Maria L; Bertoni E; Salvadori M
    Transplant Proc; 2009 May; 41(4):1204-6. PubMed ID: 19460517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
    Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
    Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
    Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
    Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sequence analysis of UL54 and UL97 genes and evaluation of antiviral susceptibility of human cytomegalovirus isolates obtained from kidney allograft recipients before and after treatment.
    Mousavi-Jazi M; Hökeberg I; Schloss L; Zweygberg-Wirgart B; Grillner L; Linde A; Brytting M
    Transpl Infect Dis; 2001 Dec; 3(4):195-202. PubMed ID: 11844151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction.
    Walker JK; Scholz LM; Scheetz MH; Gallon LG; Kaufman DB; Rachwalski EJ; Abecassis MM; Leventhal JR
    Transplantation; 2007 Apr; 83(7):874-82. PubMed ID: 17460557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure.
    Lefeuvre S; Chevalier P; Charpentier C; Zekkour R; Havard L; Benammar M; Amrein C; Boussaud V; Lillo-Le Louët A; Guillemain R; Billaud EM
    Transpl Infect Dis; 2010 Jun; 12(3):213-9. PubMed ID: 20102551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D
    Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child.
    Iwasenko JM; Scott GM; Ziegler JB; Rawlinson WD
    J Clin Virol; 2007 Oct; 40(2):152-5. PubMed ID: 17698411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients.
    Shaikh S; Jasiak-Panek N; Park JM
    Clin Transplant; 2018 Sep; 32(9):e13369. PubMed ID: 30076649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.
    Sánchez Puch S; Ochoa C; Carballal G; Zala C; Cahn P; Brunet R; Salomón H; Videla C
    J Clin Virol; 2004 Jul; 30(3):271-5. PubMed ID: 15135748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis.
    Boivin G; Goyette N; Farhan M; Ives J; Elston R
    J Clin Virol; 2012 Mar; 53(3):208-13. PubMed ID: 22237003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
    West P; Schmiedeskamp M; Neeley H; Oberholzer J; Benedetti E; Kaplan B
    Transpl Infect Dis; 2008 Apr; 10(2):129-32. PubMed ID: 17605740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of the patient's body weight on the efficacy and adverse events of valganciclovir for cytomegalovirus reactivation after hematopoietic stem cell transplantation.
    Misaki Y; Kimura SI; Kawamura M; Kawamura S; Takeshita J; Yoshino N; Yoshimura K; Gomyo A; Matsumi S; Akahoshi Y; Tamaki M; Kusuda M; Kameda K; Wada H; Kawamura K; Sato M; Terasako-Saito K; Tanihara A; Nakasone H; Kako S; Kanda Y
    Transpl Infect Dis; 2020 Jun; 22(3):e13270. PubMed ID: 32092224
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.
    Khoury JA; Storch GA; Bohl DL; Schuessler RM; Torrence SM; Lockwood M; Gaudreault-Keener M; Koch MJ; Miller BW; Hardinger KL; Schnitzler MA; Brennan DC
    Am J Transplant; 2006 Sep; 6(9):2134-43. PubMed ID: 16780548
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Ganciclovir treatment failure in adult allogeneic hematopoietic stem cell transplant recipients with cytomegalovirus infection--a single centre experience].
    Vejražková E; Hubáček P; Kutová R; Plíšková L; Košťál M; Štěpánová V; Zavřelová A; Radocha J; Malá E; Žák P
    Epidemiol Mikrobiol Imunol; 2015 Sep; 64(3):160-8. PubMed ID: 26448304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
    Gilbert C; LeBlanc MH; Boivin G
    Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients.
    Dupuis R; Harris M; Gillis K; Gerber D; Fair J; Watson R; Koslowski T; Andreoni K
    Transplant Proc; 2007 Dec; 39(10):3266-70. PubMed ID: 18089368
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intra-host diversity of drug-resistant cytomegalovirus: A case report of cytomegalovirus infection after allogeneic hematopoietic cell transplantation.
    Jung JY; Nho D; Cho SY; Lee DG; Choi SM; Kim HJ; Kim M; Oh EJ
    J Infect Chemother; 2022 Oct; 28(10):1415-1418. PubMed ID: 35810104
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.
    Gagermeier JP; Rusinak JD; Lurain NS; Alex CG; Dilling DF; Wigfield CH; Love RB
    Transpl Infect Dis; 2014 Dec; 16(6):941-50. PubMed ID: 25491023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.